The modern immunotherapy era began with high-dose interleukin-2, which demonstrated that immune activation could produce long-lasting tumor regression in a small proportion of patients with metastatic melanoma and renal cell carcinoma. The arrival of antibodies against CTLA-4, followed by inhibitors of the PD-1 and PD-L1 pathways, transformed that early proof of concept into a central pillar of cancer treatment. These drugs work by interrupting inhibitory signals that restrain T cells. CTLA-4 blockade mainly enhances T-cell priming in lymphoid tissues, while PD-1 or PD-L1 inhibition can restore the function of exhausted T cells within the tumor microenvironment. The results have included unprecedented survival improvements and long-term remission for some people with melanoma, non-small cell lung cancer, kidney cancer, and other malignancies. Yet the benefits remain uneven, and many tumors either never respond or eventually evolve around immune attack.

One of the most important newer targets is LAG-3, an inhibitory receptor found on activated T cells, regulatory T cells, B cells, and natural killer cells. LAG-3 can bind major histocompatibility complex class II molecules and suppress T-cell receptor signaling, proliferation, and production of immune-stimulating cytokines such as interleukin-2 and interferon-gamma. Its expression is particularly prominent in exhausted T cells, suggesting that it may help maintain a dysfunctional immune state inside tumors. The first approved LAG-3-directed therapy, relatlimab, is used with the PD-1 inhibitor nivolumab in advanced or metastatic melanoma. In the RELATIVITY-047 trial, the combination extended median progression-free survival to 10.1 months, compared with 4.6 months for nivolumab alone, and increased the objective response rate from 32.6 percent to 43.1 percent. Severe treatment-related adverse events occurred in 18.9 percent of patients receiving the combination, versus 9.7 percent with nivolumab alone—higher, but generally less frequent than with CTLA-4 and PD-1 combinations.

The LAG-3 story also illustrates why the next generation of immunotherapy will not be a simple succession of universal replacements for older drugs. Relatlimab has shown limited activity in patients whose disease has already progressed on checkpoint inhibitors, with an objective response rate of about 12 percent in one reported setting. Established PD-1 resistance often reflects multiple biological failures, including defective antigen presentation, exclusion of T cells from tumors, altered interferon signaling, and the emergence of immune-suppressive cell populations. Blocking one additional checkpoint may therefore be insufficient once resistance is entrenched. Still, the nivolumab-relatlimab combination has generated interest in earlier disease. Studies in melanoma have reported encouraging pathological responses before surgery, including a 57 percent pathological complete response rate in one neoadjuvant cohort and an 80 percent four-year event-free rate. Other LAG-3 strategies include fianlimab, the immune-activating fusion protein eftilagimod alpha, and bispecific antibodies designed to target both PD-1 and LAG-3 in a single molecule.

Perhaps the most powerful shift is the expansion of immunotherapy beyond the organ where a cancer began. Tissue-agnostic treatment relies on biological features shared across different tumor types, particularly defective DNA mismatch repair and high microsatellite instability. Mismatch repair proteins normally correct small copying errors made during DNA replication. When this system fails, tumors accumulate insertions, deletions, and other mutations, producing abnormal proteins known as neoantigens. These neoantigens can make cancer cells more visible to T cells, increasing the likelihood that PD-1 blockade will work. Deficient mismatch repair can result from inherited mutations associated with Lynch syndrome or from acquired epigenetic silencing, such as methylation of the MLH1 promoter. Clinicians can identify the phenotype using immunohistochemistry, polymerase chain reaction, or next-generation sequencing, allowing treatment decisions to be based on tumor biology rather than anatomical origin.

Tumor mutational burden, which measures the number of somatic mutations per megabase of tumor DNA, offers a related but less reliable signal. The underlying theory is straightforward: more mutations should create more potential neoantigens and therefore more targets for immune recognition. Clinical studies have indeed associated higher mutational burden with improved responses in diseases such as lung cancer and melanoma. However, not every mutation produces an antigen, and not every antigen is displayed effectively by a tumor cell. Measurements also vary between sequencing platforms, differ between tissue and blood samples, and can be distorted by tumor heterogeneity. As a result, mutational burden has not proved consistently dependable as a standalone predictor. A particularly striking subgroup is formed by tumors carrying pathogenic POLE proofreading mutations. These cancers can be ultramutated, densely infiltrated by lymphocytes, and exceptionally responsive to immunotherapy, even when their microscopic appearance suggests aggressive disease.

The clinical consequences of these biomarkers are becoming visible in major trials. In the KEYNOTE-158 study, pembrolizumab produced a response rate of approximately 29 percent in tumors classified as having high mutational burden, compared with 6 percent in tumors without that designation. Responses in mismatch repair-deficient or microsatellite-instability-high cancers were often remarkably durable. In advanced colorectal cancer, the phase 3 KEYNOTE-177 trial showed that first-line pembrolizumab produced a median overall survival of 77.5 months, compared with 36.7 months for chemotherapy, with five-year survival rates of 54.8 percent and 44.2 percent, respectively. The CheckMate-8HW trial further indicated that combining nivolumab with ipilimumab could outperform chemotherapy and nivolumab alone in selected patients, producing a two-year progression-free survival of 72 percent versus 14 percent with chemotherapy. In locally advanced mismatch repair-deficient rectal cancer, neoadjuvant dostarlimab has produced an especially dramatic signal: all 41 patients reported in one study achieved a clinical complete response and entered a watch-and-wait program without immediate surgery or chemoradiotherapy.

That result points toward one of the most provocative possibilities in oncology: replacing automatically scheduled surgery with response-adapted care. The concept is not yet established broadly, and longer follow-up plus prospective randomized evidence remain essential. Nevertheless, highly immunogenic tumors may eventually be managed by treating first, measuring the depth of response, and reserving surgery for residual or recurrent disease. Similar discussions are emerging in melanoma, head and neck cancer, and lung cancer. The approach would represent a profound change in the traditional sequence of cancer care, potentially preserving organs and reducing the complications of major operations. It also raises demanding technical questions. A clinical complete response does not always mean every malignant cell has disappeared, and microscopic residual disease may be difficult to detect with imaging or endoscopy. Future trials will need sensitive molecular monitoring, carefully defined retreatment strategies, and long-term surveillance to determine which patients can safely avoid surgery.

Checkpoint inhibitors are also being combined with established treatments to reshape the tumor environment before immune cells arrive. Chemotherapy can kill cancer cells and release tumor antigens, effectively providing raw material for immune priming. Antiangiogenic drugs can alter abnormal tumor blood vessels, reduce immune suppression, and improve T-cell access. In unresectable liver cancer, atezolizumab plus bevacizumab and the durvalumab-tremelimumab regimen have improved outcomes compared with the former standard, sorafenib. Median overall survival has reached roughly 16.4 to 19.2 months with atezolizumab and bevacizumab, compared with 13.4 to 13.8 months with sorafenib. The choice between regimens can depend on bleeding risk and the safety of vascular endothelial growth factor inhibition. In extensive-stage small-cell lung cancer, adding atezolizumab or durvalumab to platinum-etoposide chemotherapy has delivered the first major advance in decades, extending survival beyond the short-lived responses traditionally produced by chemotherapy alone.

The next wave reaches beyond soluble antibodies and conventional drug combinations. Bispecific antibodies and T-cell engagers can bind a tumor-associated molecule with one arm and a T-cell receptor component with the other, physically bringing immune cells into contact with malignant cells. Antibody-drug conjugates attach potent cytotoxic payloads to tumor-targeting antibodies, concentrating chemotherapy-like activity near cancer cells while potentially limiting exposure elsewhere. Adoptive cell therapies are being adapted for solid tumors through tumor-infiltrating lymphocytes, chimeric antigen receptors, and engineered T-cell receptors. TIL therapy uses a polyclonal population of tumor-reactive lymphocytes expanded from a patient’s own tumor, while CAR and TCR technologies genetically reprogram T cells to recognize selected targets. Engineered cytokines seek to preserve the immune-stimulating effects of interleukin therapies without reproducing their severe systemic toxicity. Personalized vaccines, particularly those directed against patient-specific neoantigens, aim to initiate or strengthen an immune response tailored to the mutations carried by an individual tumor.

Together, these advances reveal an emerging strategy rather than a single miracle treatment. The future of solid-tumor immunotherapy will depend on matching the right immune mechanism to the right biological context, deciding when combinations are more valuable than sequential treatment, and identifying resistance before tumors become clinically obvious. Immune-related toxicities—including pneumonitis, myocarditis, neurological complications, and permanent endocrine damage—remain a major concern as treatment moves into earlier-stage disease, where many patients may already be cured by surgery or other therapies. People with active brain metastases, poor performance status, or a need for corticosteroids have also been underrepresented in pivotal trials. The field is therefore converging on precision immuno-oncology: biomarker testing, response-adapted treatment, engineered molecules, cellular products, and increasingly individualized vaccines. If researchers can make immune attacks more selective and resistance more predictable, therapies once effective only for a minority could become durable, organ-preserving treatments across a much broader range of solid cancers.

γδ T cells constitute a distinctive subset of T lymphocytes characterized by their unique gamma and delta chain T-cell receptor (TCR). Unlike conventional αβ T cells, γδ T cells possess inherent antitumor activities and are considered promising candidates for allogeneic adoptive cell therapy due to their major histocompatibility complex (MHC)-independent recognition of tumor cells. However, clinical applications have been hampered by their relatively low targeting efficiency, which limits their ability to selectively home to and destroy malignant cells within the tumor milieu.

Addressing this limitation, the research team pioneered a precise chemical biology approach to anchor tumor-targeting antibodies onto the surface glycans of γδ T cells. By exploiting the metabolic pathways of cell-surface sialic acids, they developed a fast metabolic glycan labeling (fMGL) technique to incorporate unnatural azide-bearing sugars into terminal sialic acid residues on γδ T cells. This bioorthogonal chemical handle subsequently enabled a copper-free click chemistry reaction to conjugate αPD-L1 antibodies directly onto the cell surface, generating αPD-L1-γδ T cell conjugates with enhanced functional capabilities.

Sialic acids, which are nine-carbon acidic monosaccharides prominently located at the termini of glycan chains on cell surface proteins and lipids, were identified as optimal anchor points for antibody conjugation. Leveraging this natural cellular feature ensured that antibody conjugation occurred in a manner that preserved cellular viability and functionality. Moreover, the choice of copper-free click chemistry circumvented cytotoxic complications typically associated with copper catalysts, thereby maintaining the therapeutic potential of the engineered γδ T cells.

Functional assays conducted in vitro demonstrated that these αPD-L1-armed γδ T cells displayed significantly improved binding affinity to PD-L1-expressing tumor cells. This direct engagement triggered a cascade of immune-activating events, notably the activation of the TCR γδ, co-stimulatory receptors such as BTN3A1/2A1, and death receptor pathways. The culmination of these interactions was the robust release of cytotoxic cytokines and perforin molecules by the γδ T cells, effectively inducing pyroptosis in cancer cells—a highly inflammatory and immunogenic form of programmed cell death mediated through activation of caspase-3 and cleavage of gasdermin E (GSDME).

Pyroptosis induction is a critical therapeutic mechanism, as it not only eliminates tumor cells but also releases damage-associated molecular patterns (DAMPs) and pro-inflammatory cytokines that reinvigorate antitumor immunity. Remarkably, the study found that pyroptotic tumor cells secreted chemokines, notably CCL5, which in concert with the αPD-L1-γδ T cells, established a chemokine gradient within the tumor microenvironment (TME) conducive to the recruitment and activation of CD8⁺ cytotoxic T lymphocytes (CTLs). This recruitment occurred through the CCR5/CCL5 signaling axis, reinforcing a positive feedback loop that potentiates immune surveillance and tumor eradication.

Beyond direct tumor cell killing, the reprogramming of the TME toward an immunostimulatory state represents a foundational advancement. Solid tumors often establish immunosuppressive and metabolically hostile microenvironments that hinder the efficacy of adoptive cell therapies. The dual functionality of αPD-L1-γδ T cells—combining targeted cytotoxicity with chemoattraction of endogenous CD8⁺ T cells—paves the way for multi-faceted intervention strategies, potentially overcoming immunosuppressive barriers and mitigating tumor immune evasion.

In vivo experiments further corroborated the potent antitumor efficacy of the engineered γδ T cells in murine models bearing PD-L1-positive tumors. Systemic administration of αPD-L1-γδ T cell conjugates resulted in significant tumor regression and prolonged survival compared to unmodified γδ T cell treatments. Histological analyses revealed increased infiltration of CD8⁺ T cells within tumor tissues and elevated expression of activation markers, underscoring the immunomodulatory influence of the conjugates.

The study’s reliance on cutting-edge chemical biology techniques reflects an interdisciplinary triumph, merging glycobiology, immunology, and oncology to harness the full potential of cellular therapies. This modular conjugation platform offers exceptional versatility, allowing for the future attachment of diverse targeting antibodies against various tumor antigens, enhancing the adaptability of γδ T cell therapies across multiple cancer types.

Additionally, safety assessments revealed that the conjugation strategy preserved the proliferative and functional capacities of γδ T cells without noticeable off-target effects or systemic toxicity. The rapid and efficient labeling methodology is amenable to clinical-scale manufacturing, setting the stage for translation into human trials.

The work was spearheaded by Professor Jian Lin, Xing Chen, Hongyan Guo, and Long Chen, whose collaborative efforts exemplify the synergy between chemical innovation and immunotherapeutic development. Their contribution propels γδ T cell adoptive therapies towards becoming versatile and potent weapons against refractory solid tumors.

This novel approach signifies a paradigm shift in cancer immunotherapy by augmenting the tumor-targeting precision of γδ T cells while simultaneously mobilizing endogenous adaptive immune components. By reconfiguring the tumor microenvironment to favor immune activation, this strategy addresses one of the pivotal challenges in deploying cellular therapies against solid malignancies.

Future directions may include expanding the repertoire of conjugated antibodies to target heterogeneous tumor antigen profiles, optimizing dosing regimens, and integrating this strategy with other immunomodulatory agents such as checkpoint inhibitors or cytokine therapies. The translational potential is immense, harboring implications for personalized medicine and combination immunotherapy protocols.

As tumor immunology continues to unravel complexities of tumor-immune interplay, approaches such as antibody-armed γδ T cells stand at the forefront of therapeutic innovation, harnessing the power of synthetic biology to rewrite the rules of immune-mediated cancer destruction.

Subject of Research: Enhancement of γδ T cell-based cancer immunotherapy through antibody conjugation and tumor microenvironment modulation.

Article Title: αPD-L1-armed γδ T Cells Show Enhanced Anti-tumor Activity and Reprogram the Tumor Microenvironment via Chemokine Signaling to Potentiate CD8⁺ T-Cell Recruitment and Anti-Tumor Immunity

Web References: http://dx.doi.org/10.1093/nsr/nwaf256

Image Credits: ©Science China Press

Keywords

γδ T cells, cancer immunotherapy, antibody conjugation, metabolic glycan labeling, PD-L1, pyroptosis, tumor microenvironment, chemokine signaling, CD8⁺ T cells, CCR5/CCL5 axis, adoptive cell therapy, click chemistry